Table 2. Descriptive statistics of the study population stratified according to disease progression, and Cox regression models of association of clinical factors with the risk of disease progression.
| No PCa progression n = 115 (78.2) | PCa progression n = 32 (21.7) | Univariable | Multivariable (*) | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |||
| Age (years) | 67 (61 - 71) | 65 (61 - 70) | 0.99 (0.94 - 0.105) | 0.8 | ||
| BMI (kg/m^2) | 25.7 (23.7 - 27.8) | 25.1 (23.7 - 28.5) | 0.99 (0.87 - 1.12) | 0.8 | ||
| PV (mL) | 37.0 (30.0 - 46.0) | 33.0 (25.0 - 48.5) | 0.98 (0.96 - 1.01) | 0.2 | ||
| PSA (ng/mL) | 6.3 (5.0 - 8.1) | 6.3 (5.1 - 7.9) | 1.13 (0.93 - 1.37) | 0.2 | ||
| BPC (%) | 28.5 (20.0 - 45.4) | 47.0 (20.3 - 64.2) | 1.02 (1.01 - 1.04) | 0.001 | ||
| Clinical stage | ||||||
| T1c | 59 (51.3) | 18 (56.3) | Ref. | - | ||
| T2b | 56 (48.7) | 14 (43.7) | 2.31 (1.12 - 4.76) | 0.024 | ||
| 2012 Briganti nomogram score | 6.0 (4.0 – 11.0) | 7.5 (4.0 - 16.5) | 1.06 (1.02 - 1.09) | 0.001 | 1.06 (1.02 - 1.09) | 0.001 |
Abbreviations: HR = odds ratio; CI = confidence interval; BMI = body mass index; PV = prostate volume; PSA = prostate-specific antigen; BPC = biopsy positive cores. / (*) according to Wald’s forward method. Continuous variables are reported as median (interquartile range) while categorical factors as frequencies (percentage).